The global non-small cell lung cancer market garnered a market value of USD 10 Billion in 2023 and is expected to accumulate a market value of USD 20 Billion by registering a CAGR of 7.2% in the forecast period 2023 to 2033. This rapid expansion can be ascribed to an expanding patient population, the anticipated introduction of many medications, and increased expenditure by market players in NSCLC research and development.
The rising incidence of NSCLC globally owing to increased air pollution and smoking behaviors among people is expected to boost the market in the approaching years. According to the American Cancer Society, about 224,390 new lung cancer patients will be diagnosed in the USA year 2016. Lung cancer is one of the leading causes of mortality around the globe.
The existence of a robust pipeline for NSCLC is expected to drive growth in the next years. For example, fruquintinib (HMPL-013),a medicine being developed to treat advanced non-small cell lung cancer, is now in clinical trials. Furthermore, Merck KGaA's Avelumab is now under development. It is a PD-L1 antibody that is 100% human. As a result, the market is likely to be driven by the development of such sophisticated therapies throughout the forecast period.
Researchers at Brigham and Women's Hospital in Massachusetts profess to have developed a deep learning system that can identify and segment non-small cell lung cancer (NSCLC) tumors on CT scans in under a minute in a paper published in October 2022. The researchers also discovered that radiation oncologists who used the application were 65% more productive than doctors who did not use the technology in simulated clinics.
| Data Points | Key Statistics |
|---|---|
| Expected Market Value (2023) | USD 10 Billion |
| Anticipated Forecast Value (2033) | USD 20 Billion |
| Projected Growth Rate (2023 to 2033) | 7.2% CAGR |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
The global demand for non-small cell lung cancer treatment is projected to increase at a CAGR of 7.2% during the forecast period between 2023 and 2033, reaching a total of USD 20 Billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 6%.
During the projected period, the worldwide non-small cell lung cancer market is predicted to grow significantly. Increasing occurrences of lung cancer owing to smoking, air pollution (asbestos, cadmium, and radon), HIV infection, and population expansion are a few of the market's growth factors.
In the anticipated time, North America is expected to have the greatest market share, followed by Europe. Because of rising smoking rates in emerging nations, the Asia Pacific region is expected to be a substantial contributor to the NSCLC market.
Growing Environmental Pollution to Improve Market Maintenance and Performance
The rise in NSCLC incidence, which now accounts for about 85% of all lung cancer cases worldwide, is related to an increase in long-term cigarette use. Cigarette smoke, which contains at least 73 known carcinogens, is expected to cause an upsurge in cancer cases in the near future.
The growth in environmental pollution is a serious issue that requires stronger regulations to address. However, high levels of pollution have been related to an increase in cancer diagnoses in those who have been exposed to it for a longer period of time. Cancer detection has improved, making the delivery of lung cancer treatments such as chemotherapy and surgery simpler than ever before, improving the NSCLC treatment market share's advancement over the projection period.
Reimbursements and Expanding Medical Insurance to Accelerate Market Growth
Several insurance companies expansion and inclusion of cancer-related treatment and care are expected to boost the NSCLC treatments business throughout the forecast period. The growing pace of substantial research efforts aimed at examining various cancer kinds, with NSCLC being a key emphasis, may provide appealing options in the future.
Increased governmental and private sector support for funding for improved patient care, effective treatment, and the use of new diagnostic tools will provide significant possibilities for active players.
Strict High Standards for Any New Treatment to Hamper Market Growth
Treatment for NSCLC must be licensed by regulatory agencies with stringent criteria and testing techniques, which may limit market development. GSK states that both arms of its phase 2/3 non-small cell lung cancer (NSCLC) clinical study had passed the parameters for progressing to the next stage of the inquiry, a step toward potentially validatory results.
GSK's anti-TIM-3 antibody is going onto a pivotal trial following favorable findings in the mid-stage of the research, consolidating Big Pharma's position as the leader in a smaller field that also includes Novartis.
The dearth of Lung Transplant Organs to Stymie Market Growth
The lower life expectancy of patients undergoing NSCLC therapy, which is limited by the lack of lung organ transplants, is expected to diminish growth potential throughout the projected period.
Existence of Fewer Onerous Regulatory Clearance Processes and a Big Patient Pool Widening Profit Margins
In 2022, Asia Pacific was the fastest-growing region for the NSCLC market. This was mostly owing to the existence of less onerous regulatory clearance processes and a big patient pool. Because of the availability of modern pharmaceuticals, a developed economy, and a huge patient pool, Japan and China contributed the most to the Asia Pacific region.
This development is expected to be led by national markets in China, South Korea, Japan, and Kazakhstan. As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 6.7% during the assessment period 2023 to 2033.
The arrival of Newer Medication and Strong Investment by Companies to Fuel Market Growth
North America is projected to retain its dominance and will be one of the most profitable areas for the NSCLC market over the forecast period. This is due to the arrival of newer medications, strong investment by companies, acceptance of expensive drugs, and increasing government financing for Research and Development operations.
NSCLC is the leading cause of death among the many forms of cancer. Even with advances in therapy, NSCLC is still frequently identified after it has progressed, despite advances in screening. North America is expected to grow at a CAGR of 7.1% during the assessment period 2023 to 2033.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
The Chemotherapy Segment to be the Most Preferred Treatment Type
On the basis of treatment type, the market is segmented into Chemotherapy, Targeted Therapy, and Immunotherapy. During the projection period, the chemotherapy segment is expected to dominate the bulk of the treatment-based segment.
Key start-up players in the Non-Small Cell Lung Cancer are offering new and innovative product lines to consolidate their market presence, these aforementioned start-ups have left no stone unturned. Some specific instances of key Non-Small Cell Lung Cancer start-ups are as follows:
The primary strategies followed by the players include collaborations and acquisitions of well-established firms, the creation of novel medications, and broadening the indications for current treatments. Key players in the Non-Small Cell Lung Cancer market are Novartis Pharmaceuticals, Merck KGaA, Eli Lilly and Company, Hoffmann-La Roche, Xcovery, BeyondSpring Pharmaceuticals, OSE Immunotherapeutics, Sanofi, Takeda, AbbVie.
Recent Developments:
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 10 Billion |
| Market Value in 2033 | USD 20 Billion |
| Growth Rate | CAGR of 7.2% from 2022 to 2032 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Cancer Type, Treatment, Region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Germany, UK, France, Spain, Italy, China, Japan, South Korea, Singapore, Thailand, Indonesia, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Companies Profiled | F. Hoffmann-La Roche Ltd.; Bristol-Myers Squibb Company; Pfizer Inc.; AstraZeneca; Novartis AG; Eli Lilly and Company; Merck & Co., Inc.; Boehringer Ingelheim International GmbH; Sanofi; Astellas Pharma Inc. |
| Customization | Available Upon Request |
FMI projects the global non-small cell lung cancer market to expand at a 72% value CAGR by 2033
The global non-small cell lung cancer market is estimated at a market value of USD 10 Billion
The global non-small cell lung cancer market is expected to garner a market value of USD 20 Billion
North America is forecast to be the most lucrative for non-small cell lung cancer market growth.
Novartis Pharmaceuticals, Merck KGaA, Eli Lilly and Company, Hoffmann-La Roche, Xcovery, BeyondSpring Pharmaceuticals, OSE Immunotherapeutics, Sanofi, Takeda, and AbbVie are some prominent non-small cell lung cancer manufacturers
As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 6.7% during the assessment period 2023 to 2033.
Europe is expected to grow at a CAGR of 7% during the assessment period 2023 to 2033.
The chemotherapy segment is expected to hold the largest market share for non-small cell lung cancer in the forecast period 2023 to 2033.
| Estimated Market Size (2024E) | USD 1.4 billion |
|---|---|
| Projected Market Value (2034F) | USD 2.5 billion |
| Value-based CAGR (2024 to 2034) | 5.7% |
| Estimated Market Size (2024E) | USD 37.5 billion |
|---|---|
| Projected Market Value (2034F) | USD 112.8 billion |
| Value-based CAGR (2024 to 2034) | 11.7% |
Explore Therapy Area Insights
View Reports
Non-Small Cell Lung Cancer Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
